FDMT News and Press, 4D Molecular Therapeutics Inc. From 08/01/25

A look at the top 10 most actives in the United States Erayak Power Solution Group Inc. (RAYA) rose 41.4% to $0.084 on volume of 564,200,836 shares LOBO EV TECHNOLOGIES LTD. (LOBO) rose 118.7% to $0.7864 on volume of 419,806,285 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose...

2025-08-01 15:11:44 ET DENVER, Colo., Aug 01, 2025 ( 247marketnews.com )- As the final trading hour approaches, watch for names building into potential breakouts, or setting up for extended moves after-hours. 4D Molecular (NASDAQ:FDMT) is having its strongest day since its rally...

2025-08-01 10:57:07 ET DENVER, Colo., Aug 01, 2025 ( 247marketnews.com )- While the major indices grind sideways, traders are finding alpha in small- and mid-cap catalysts and this week, the opportunities are flashing across biotech, fintech, real estate, and gaming crossovers. ...

A look at the top 10 most actives in the United States Erayak Power Solution Group Inc. (RAYA) rose 13.0% to $0.0671 on volume of 108,288,360 shares Tenon Medical Inc. (TNON) rose 73.5% to $1.77 on volume of 72,377,754 shares Marwynn Holdings Inc. (MWYN) rose 56.7% to $1.41 on volume of 67,...

4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and anatomic control Phase 3 dose (3E10 vg/eye) achieved clinically...

EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefi...

2025-07-02 16:47:13 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Historical earnings data for 4D Molecular Therapeutics Financi...

4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline shift, as announced in January 2025 EMERYVILLE, Cali...

2025-05-08 17:59:48 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression 4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment Cantor analysts call for RFK Jr. replacement following ousting of ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027 ...